- Home
- VMEO vs GYRE Comparison
VMEO vs GYRE Comparison
Compare VMEO & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMEO
- GYRE
- Stock Information
- Founded
- VMEO 2004
- GYRE 2002
- Country
- VMEO United States
- GYRE United States
- Employees
- VMEO N/A
- GYRE N/A
- Industry
- VMEO Computer Software: Prepackaged Software
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- VMEO Technology
- GYRE Health Care
- Exchange
- VMEO Nasdaq
- GYRE Nasdaq
- Market Cap
- VMEO 1.1B
- GYRE 1.3B
- IPO Year
- VMEO N/A
- GYRE N/A
- Fundamental
- Price
- VMEO $6.49
- GYRE $10.84
- Analyst Decision
- VMEO Buy
- GYRE
- Analyst Count
- VMEO 4
- GYRE 0
- Target Price
- VMEO $7.50
- GYRE N/A
- AVG Volume (30 Days)
- VMEO 1.4M
- GYRE 126.3K
- Earning Date
- VMEO 11-04-2024
- GYRE 11-13-2024
- Dividend Yield
- VMEO N/A
- GYRE N/A
- EPS Growth
- VMEO 290.90
- GYRE N/A
- EPS
- VMEO 0.20
- GYRE N/A
- Revenue
- VMEO $419,394,000.00
- GYRE $105,033,000.00
- Revenue This Year
- VMEO $1.32
- GYRE $25.32
- Revenue Next Year
- VMEO $2.07
- GYRE $12.95
- P/E Ratio
- VMEO $34.88
- GYRE N/A
- Revenue Growth
- VMEO 0.52
- GYRE N/A
- 52 Week Low
- VMEO $3.43
- GYRE $8.26
- 52 Week High
- VMEO $7.90
- GYRE $30.40
- Technical
- Relative Strength Index (RSI)
- VMEO 53.37
- GYRE 54.43
- Support Level
- VMEO $6.77
- GYRE $9.61
- Resistance Level
- VMEO $7.06
- GYRE $12.58
- Average True Range (ATR)
- VMEO 0.28
- GYRE 1.12
- MACD
- VMEO -0.06
- GYRE 0.16
- Stochastic Oscillator
- VMEO 21.68
- GYRE 79.51
About VMEO Vimeo Inc.
Vimeo Inc is the all-in-one video software solution, providing the full breadth of video tools through a software-as-a-service model. Its comprehensive and cloud-based tools empower its users to create, collaborate and communicate with video on a single, turnkey platform. The company derives its revenue from SaaS subscription fees paid by customers for subscription plans.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.